SP0137 Low-Dose IL-2 Therapy in Refractory SLE: Early Insights from a Phase I/IIA Clinical Trial von Humrich, J.Y.

Volltext

SP0189 Induction of Remission by Low-Dose IL-2-Therapy in One SLE Patient with Increased Disease Activity Refractory to Standard Therapies von Humrich, J.Y.

Volltext

A3.12 Intrarenal Foxp3+ Regulatory T Cells Expansion and Decreased Number of Infiltrating CD4+ T Cells in Murine Lupus by IL-2 Therapy von Rose, A, Humrich, JY, Riemekasten, G

Volltext

AB0193 IL-2 therapy in murine lupus nephritis leads to an expansion of intrarenal FOXP3+ regulatory T cells von Rose, A., Humrich, J.Y., Riemekasten, G.

Volltext

A7.06 Low-dose IL-2 therapy in refractory sle: Insights from a phase I/IIA clinical trial von Humrich, JY, von Spee-Mayer, C, Siegert, E, Bertolo, M, Abdirama, D, Rose, A, Enghard, P, Radbruch, A, Burmester, GR, Riemekasten, G

Volltext

SAT0160 IL-2 deprivation of FOXP3+ TREG in systemic lupus erythematosus von von Spee, C., Wassermann, N., Humrich, J.Y., Riemekasten, G.

Volltext

A9.14 Regulatory T Cell Abnormalities in Patients with SLE Suggest an IL-2-Based Immunotherapy von Spee, C von, Wassermann, N, Humrich, JY, Riemekasten, G

Volltext

AB0204 Targeting of steady state DC via DEC205 and 33D1 expands regulatory T cells but does not restore tolerance in murine lupus von Humrich, J.Y., Undeutsch, R., Weigert, O., Reiser, J., Seriot, L., Riemekasten, G.

Volltext

SAT0165 Low-dose IL-2 therapy selectively expands regulatory T cells and suppresses murine lupus von Humrich, J.Y., Kloke, L., Rose, A., von Spee, C., Klaus, A., Undeutsch, R., Riemekasten, G.

Volltext

Mature monocyte‐derived dendritic cells respond more strongly to CCL19 than to CXCL12: consequences for directional migration von Humrich, Jens Y., Humrich, Jan H., Averbeck, Marco, Thumann, Peter, Termeer, Christian, Kämpgen, Eckhart, Schuler, Gerold, Jenne, Lars

Volltext